Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of...
87 insider purchases on record · latest filing 2025-12-16.
Insiders have also filed 81 sale transactions at RLMD.